Pharmasyntez has registered Saterex® (INN Gosogliptin), an original hypoglycemic agent, in Uzbekistan and Kyrgyzstan that will allow patients with type 2 diabetes mellitus in these countries to receive affordable treatment with the innovative drug.
Saterex® is the only original domestic drug product of the group of DPP-4 inhibitors for the treatment of type 2 diabetes mellitus recognized by the Russian endocrinologists. The drug is effective both as monotherapy and in combination with metformin; it also has a good safety profile (low risk of hypoglycemia) and is patient-friendly as it is taken once a day.
In the Russian Federation, Saterex® is included in the List of Vital and Essential Drugs according to Resolution of the Government of the Russian Federation No. 2406-R of October 12, 2019, and in the clinical practice guidelines (Algorithms for Specialized Medical Care for Patients with Diabetes Mellitus, edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorova, 9th edition, Moscow, 2019).
For more information about the drug, please visit saterex.ru